LungArchives
A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung Cancer
Lung 5 min.
Pembrolizumab administered by intravenous (IV) infusion was first approved in 2014 for treatment of advanced melanoma and has since gained regulatory approval in many countries for multiple tumor types and disease stages, including metastatic non-small cell lung cancer (mNSCLC) [1, 2]. Pembrolizumab...
Three-dimensional analysis to predict recurrence of pure-solid non-small cell lung cancer after segmentectomy
Lung 4 min.
The Japan Clinical Oncology Group 0802 (JCOG 0802) recently conducted a pivotal randomized controlled trial [1] that compared the non-small cell lung cancer (NSCLC) survival rates of lobectomies and segmentectomies for tumors less than 2 cm in diameter. These findings highlighted the value of the segmentectomy...
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
Lung 1 min.
Squamous non-small-cell lung cancer (NSCLC) is associated with worse clinical outcomes than non-squamous NSCLC, but treatment options are scarce. We aimed to evaluate the efficacy and safety of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as a first-line therapy for patients with...
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
Lung 1 min.
Limertinib is a new third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This study aimed to prospectively assess the efficacy and safety of limertinib versus gefitinib as a first-line treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) with...
